UCB shares jumped 13%, erasing year-to-date losses, after the company raised its annual guidance for the second time this year.
The boost was driven by strong U.S. demand for its blockbuster immunology drug Bimzelx, which has become a key revenue driver for the Belgian biotech firm.
Analysts welcomed the upbeat outlook, noting that Bimzelx's performance reflects growing adoption in the immunology market and solid execution by UCB.
The company now expects full-year results to exceed previous forecasts, reinforcing investor confidence in its pipeline and commercial strategy.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing